Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.
Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ. Aldape K, et al. Among authors: rich jn. Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. Nat Rev Clin Oncol. 2019. PMID: 31150022 No abstract available.
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Gururangan S, et al. Among authors: rich jn. Neuro Oncol. 2001 Oct;3(4):246-50. doi: 10.1093/neuonc/3.4.246. Neuro Oncol. 2001. PMID: 11584894 Free PMC article. Clinical Trial.
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: rich jn. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Quinn JA, et al. Among authors: rich jn. J Clin Oncol. 2002 May 1;20(9):2277-83. doi: 10.1200/JCO.2002.09.084. J Clin Oncol. 2002. PMID: 11980998 Clinical Trial.
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Quinn JA, et al. Among authors: rich jn. J Clin Oncol. 2003 Feb 15;21(4):646-51. doi: 10.1200/JCO.2003.01.009. J Clin Oncol. 2003. PMID: 12586801 Clinical Trial.
Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Rich JN, et al. J Clin Oncol. 2004 Jan 1;22(1):133-42. doi: 10.1200/JCO.2004.08.110. Epub 2003 Nov 24. J Clin Oncol. 2004. PMID: 14638850 Clinical Trial.
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Sampson JH, et al. J Neurooncol. 2003 Oct;65(1):27-35. doi: 10.1023/a:1026290315809. J Neurooncol. 2003. PMID: 14649883 Clinical Trial.
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Quinn JA, et al. J Clin Oncol. 2005 Oct 1;23(28):7178-87. doi: 10.1200/JCO.2005.06.502. J Clin Oncol. 2005. PMID: 16192602 Clinical Trial.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. Among authors: rich jn. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial.
306 results